SP1-independent inhibition of FOXM1 by modified thiazolidinediones.

Seyed Amirhossein Tabatabaei Dakhili, David J Pérez, Keshav Gopal, Moinul Haque, John R Ussher, Khosrow Kashfi, Carlos A Velázquez-Martínez

European journal of medicinal chemistry 2021 Jan 01

filter terms:

This research article describes an approach to modify the thiazolidinedione scaffold to produce test drugs capable of binding to, and inhibit, the in vitro transcriptional activity of the oncogenic protein FOXM1. This approach allowed us to obtain FOXM1 inhibitors that bind directly to the FOXM1-DNA binding domain without targeting the expression levels of Sp1, an upstream transcription factor protein known to activate the expression of FOXM1. Briefly, we modified the chemical structure of the thiazolidinedione scaffold present in anti-diabetic medications such as pioglitazone, rosiglitazone and the former anti-diabetic drug troglitazone, because these drugs have been reported to exert inhibition of FOXM1 but hit other targets as well. After the chemical synthesis of 11 derivatives possessing a modified thiazolidinedione moiety, we screened all test compounds using in vitro protocols to measure their ability to (a) dissociate a FOXM1-DNA complex (EMSA assay); (b) decrease the expression of FOXM1 in triple negative-breast cancer cells (WB assay); (c) downregulate the expression of FOXM1 downstream targets (luciferase reporter assays and qPCR); and inhibit the formation of colonies of MDA-MB-231 cancer cells (colony formation assay). We also identified a potential binding mode associated with these compounds in which compound TFI-10, one of the most active molecules, exerts binding interactions with Arg289, Trp308, and His287. Unlike the parent drug, troglitazone, compound TFI-10 does not target the in vitro expression of Sp1, suggesting that it is possible to design FOXM1 inhibitors with a better selectivity profile. Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Citation

Seyed Amirhossein Tabatabaei Dakhili, David J Pérez, Keshav Gopal, Moinul Haque, John R Ussher, Khosrow Kashfi, Carlos A Velázquez-Martínez. SP1-independent inhibition of FOXM1 by modified thiazolidinediones. European journal of medicinal chemistry. 2021 Jan 01;209:112902